<?xml version="1.0" encoding="UTF-8"?>
<p>A total of 2578 patients registered at our institution between January 2004 and December 2013 were initially positive for HCV antibody and had no other chronic liver disease, such as hepatitis B virus (HBV) infection, alcoholic liver disease, autoimmune hepatitis, primary biliary cirrhosis, or Wilson disease (Fig. 
 <xref ref-type="fig" rid="F1">1</xref>). Anti-HCV and HCV RNA levels were positive for more than 6 months in all patients. Of these 2578 patients, those who did not undergo an examination of HCV RNA (n = 445), negative for HCV RNA (n = 514), follow-up &lt;6 months, and those with a history of HCC or another malignancy (n = 67) were excluded. Of the remaining 1292 patients, 81 treated with a conventional interferon (IFN)-based therapy and 35 with a history of a new drugs (n = 35) were also excluded. Patients treated with PEG-IFN/RBV after conventional IFN-based therapy were enrolled in the study. Accordingly, 1176 patients were finally enrolled in this study, and their database records were retrospectively analyzed.
</p>
